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Whole genome sequencing (WGS) prom-
ises to be transformative for the practice of
clinical microbiology, and the rapidly falling
cost and turnaround time mean that this
will become a viable technology in diagnos-
tic and reference laboratories in the near
future. The objective of this article is to
consider at a very practical level where, in
the context of a modern diagnostic micro-
biology laboratory, WGS might be cost-
effective compared to current alternatives.
We propose that molecular epidemiology
performed for surveillance and outbreak
investigation and genotypic antimicrobial
susceptibility testing for microbes that are
difficult to grow represent the most imme-
diate areas for application of WGS, and
discuss the technical and infrastructure
requirements for this to be implemented.
Introduction
Advances in whole genome sequencing
(WGS) [1,2] have resulted in a reduction in
the full economic cost of sequencing a
typical bacterial genome to as little as £40
(from extracted DNA to genome sequence).
In addition, the speed of sequencing is
increasing, with the prospect in the near
future of a reduction in the time taken to
sequence a microbial genome from several
days or weeks to just hours. The combina-
tion of low cost and rapid turnaround time
will mean that pathogen WGS can cross
the divide between microbial research and
the practice of diagnostic microbiology [3–
6]. This holds the potential to transform
our understanding of the evolution of
pathogens and the global spread of antimi-
crobial resistance, a problem identified by
the World Health Organization (WHO) as
one of the three greatest threats to human
health [7]. This step change could also
represent the most significant advance in
diagnostic microbiology and surveillance
since the advent of in vitro culture.
The aim of this article is to discuss the
potential utility and impact of pathogen
WGS as a routine tool for diagnostic and
public health microbiology, together with
the technical and infrastructure require-
ments for this to be realised. The health-
care system in England is used as an
example, but the findings are transferable
to other sufficiently resourced countries.
The differences between the various se-
quencing technologies [8,9] and the les-
sons learned from the use of WGS as a
retrospective tool for scientific research
have been reviewed elsewhere [10–18]
and will not be discussed here.
Overview of the Current
Diagnostic Paradigm in
Diagnostic and Public Health
Microbiology
Deciding where to employ pathogen
WGS in routine diagnostic microbiology
requires consideration of the processes
used in current laboratory practice. In
very broad terms this is made up of four
main stages, starting with detection (or
not) of a pathogen in a sample. If a
clinically relevant pathogen is detected,
then this may be further tested for
identification, drug susceptibility, and
epidemiological typing. This simplified
description best fits bacteria and fungi
and is less accurate for viruses. Detecting
the presence of a virus and species
identification are often performed by the
initial test (for example, a species-specific
PCR), and susceptibility testing and typing
are not performed for many of the viruses
detected in the routine laboratory. But
taken overall, each stage represents a
reasonably circumscribed activity in rou-
tine laboratories, each of which is associ-
ated with a step-wise decrease in the
number of samples analysed and an
inverse association with turnaround times,
labour, and costs. We have represented
these features in a schematic illustration in
Figure 1, the purpose of which is to
provide a comparator (used later in the
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article) against which to describe the
possible impact of WGS.
Detection and Identification
Unlike diagnostic virology, which has
already undergone a major shift from
phenotypic to PCR-based genotypic tests,
the detection of most bacteria and fungi
still relies on culture-based methods devel-
oped for the most part over a century ago
(exceptions include molecular assays such
as those used to detect Chlamydia, methi-
cillin-resistant Staphylococcus aureus (MRSA),
and drug-resistant Mycobacterium tuberculosis,
discussed below). What has changed
recently is the degree of automation
available for bacterial culture [19]. Agar
plates can now be delivered, inoculated,
incubated, and imaged by fully automated
conveyor belt systems, reducing the
amount of labour required at each of the
multiple steps involved in sample process-
ing. This development has been driven by
the need to reduce costs while maintaining
or increasing throughput, resulting in an
on-going transition towards laboratory
amalgamation and the expansion of cen-
tralised facilities, adoption of around the
clock working practices, and a shift in the
workforce skill mix towards a greater
reliance on assistants and a reduction in
the number of qualified laboratory tech-
nicians.
Organism culture is both cheap and
appropriate for first-line microbiological
screening processes. The turnaround time
is around 1–2 days for many samples,
although longer for those samples that
require more prolonged incubation (such
as blood cultures). For most specimens,
this initial detection step is also the last as
the majority of samples are reported as
‘‘negative’’ or ‘‘no significant growth.’’ For
example, MRSA screening of 1,662 pa-
tients admitted to Addenbrooke’s Hospital
over a period of 1 week identified only 22
carriers (1.3%).
Once a significant bacterial or fungal
isolate is detected, species identification is
almost always performed. This may pro-
vide early prediction of antimicrobial
susceptibility, clues as to the potential for
disease progression, and can direct further
investigations and clinical management.
Identification is traditionally achieved
using a range of approaches including
manual kits (e.g. latex agglutination for
Staphylococcus aureus). More recently, the
emergence of MALDI-TOF has permitted
accurate species identification within min-
utes directly from a single colony at only a
fraction of the cost of traditional tech-
niques and is likely to become the default
front-line identification tool in clinical
bacteriology [20,21]. Moreover, there is
a drive to apply this technology directly to
samples from positive blood-culture bottles
and, in some cases, even to primary
samples [22].
A small number of pathogens require
more extensive testing because of their
pathogenic potential or infection control
importance. This includes more detailed
identification of certain organisms, or
detection of specific virulence factors or
toxins. For example, Bordetella pertussis
infections are relatively rare in the United
Kingdom but require rapid identification,
confirmation, and characterisation. Much
of this workload is handled by specialist
reference laboratories, and usually adds a
week to the turnaround time, although
other tests can take considerably longer.
Drug Susceptibility Testing
Drug susceptibility testing is currently
undertaken for significant bacterial patho-
gens using standardised methods such as
disk diffusion or automated systems. This
process adds at least 1 further day to the
turnaround time but can take significantly
longer for some organisms, as discussed in
the next section. In contrast, susceptibility
is not routinely performed for the vast
majority of viruses. HIV is the most
prominent exception, which is performed
using Sanger sequencing and typically
takes between 1 and 2 weeks (J. Greatorex,
personal communication). HIV genotyp-
ing will be discussed below.
Epidemiological Typing
Microbial genotyping is also carried out
to support infection control teams investi-
gating putative hospital-associated out-
breaks involving pathogens such as
MRSA. In some cases, extended antimi-
crobial susceptibility patterns can provide
timely evidence of the introduction and
transmission of a new strain if it has a
different susceptibility pattern to those
seen in the preceding weeks or months
[23]. In most cases, however, outbreak
investigations must be supported by refer-
ence laboratory genotyping, the protocol
for which is limited by three factors. First,
isolate collection and batching introduces
a delay; second, the turnaround time of at
least 1 week for the test itself introduces a
further delay (and together, these factors
mean that genotyping information does
not directly inform the management of the
patient from whom the isolate was obtained,
or of their contacts); and third, the current
tools such as spa-typing and pulsed-field gel
electrophoresis have a limited resolution,
particularly to differentiate strains belong-
ing to the same bacterial clone (such as
EMRSA-15, currently the dominant hospi-
tal-associated MRSA clone in the United
Kingdom [24]).
Uses for Routine Pathogen WGS
Epidemiological Typing
An obvious application for WGS is
epidemiological typing to detect laborato-
ry cross-contamination, to define trans-
mission pathways of pathogens, and to
support outbreak investigations [25]. Cur-
rent bacterial genotyping techniques have
a limited resolution because they only
interrogate small regions of the microbial
genome [14,26,27], whereas sequencing of
the entire genome provides the ultimate
resolution for epidemiological studies, as
demonstrated by several recent studies
including outbreaks of cholera in Haiti
and E. coli O104:H4 in Germany [27–50].
For organisms whose rate of genomic
change is sufficiently high, the resolution
obtained may make it possible to recon-
struct transmission pathways between
healthcare centres, hospital wards, or even
patients on the same ward [23,51–57].
This would provide a mechanism for
monitoring outbreaks in real-time and
highlight daily opportunities for infection
control [23,58]. However, well-designed
studies are required for each pathogen to
determine whether routine use of WGS
would be cost-effective.
Drug Susceptibility Testing
The role of pathogen WGS in antimi-
crobial susceptibility testing is more limit-
ed. This is because the sensitivity and
robustness of phenotypic susceptibility
testing will be difficult to match with
genotypic tests, in part due to incomplete
data linking genotype to phenotype.
Moreover, phenotypic testing is inexpen-
sive. In the event that WGS was adopted
for epidemiological purposes and was
significantly faster than the 18–24 hours
taken for standard disc susceptibility
testing, then it could complement pheno-
typic testing, which would still be neces-
sary to detect resistance encoded by novel
mechanisms. For example, it could be
used to rule in resistance for certain
antibiotics where known drug-resistance
mutations or genes are found before
phenotypic results become available [23].
Where discrepancies between the antimi-
crobial susceptibility genotype and pheno-
type occur, phenotypic results could be
repeated as part of a process to establish
the basis for this. WGS as a sole diagnostic
method to detect resistance is only viable
where complete or near-complete congru-
ence exists between phenotype and geno-
type, and where phenotypic testing is
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Figure 1. Potential impact of whole genome sequencing in diagnostic and public health microbiology. Clinical samples processed by
diagnostic microbiology laboratories commonly pass through up to four stages, characterised by a stepwise decrease in the number of samples
analysed at each successive stage and an inverse association with turn-around time (TAT), labour, and costs (shown in dark blue). Detection,
identification, and susceptibility testing in virology are achieved using serological or molecular methods, whereas bacteriology generally relies on
phenotypic methods. Epidemiological typing is only done for a handful of organisms using molecular and sometimes phenotypic methods. The most
compelling immediate applications for WGS are molecular epidemiology for the purposes of surveillance and outbreak investigation (e.g. for MRSA)
and drug susceptibility testing for organisms that are either slow growers or difficult to culture (e.g. MTBC and HIV). This is likely to lead to more
samples being typed than is currently the case (depicted in purple), all while drastically reducing turnaround times, provided that WGS is performed
in a regional or local laboratory rather than a reference centre. Assuming that this information enables cost-effective clinical interventions, the
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prohibitively slow. There are two good
examples where this is the case.
The first relates to slow-growing bacte-
ria, amongst which the M. tuberculosis
complex (MTBC), the causative agent of
tuberculosis, is the most prominent ex-
ample. The slow growth rate of MTBC
means that the turnaround time of full
phenotypic susceptibility testing is mea-
sured in weeks, but its genomic homoge-
neity and the fact that resistance can only
arise through point mutations or small
insertions/deletions makes it an ideal
target for genotypic testing [59]. Probe-
based hybridisation tests have been used
for a number of years, but their utility has
been limited because they interrogate
only a small number of loci responsible
for drug resistance and are relatively
labour-intensive [60]. More recently, the
WHO has endorsed another genotypic
test, namely the Cepheid Xpert MTB/
RIF assay, which can simultaneously
distinguish MTBC from other acid-fast
bacteria and detect rifampicin resistance.
This is achieved in an automated fashion
directly from sputum within 2 hours
[61,62] and provides rapid information
to the treating clinician and infection
control team. This test could be comple-
mented by WGS of the cultured organism
(i.e. from a positive MGIT culture tube),
which could, over time, replace the
remaining diagnostic functions including
the precise species identification, suscep-
tibility testing for the remaining antibiot-
ics, and epidemiological typing, which are
currently achieved using a myriad of
techniques at reference laboratories (Fig-
ure S1) [58,63].
The second example relates to viral
genotyping [64,65], most importantly for
HIV. Tests that determine viral tropism
(which receptor HIV uses to enter cells)
are required before the use of a cell entry
inhibitor (e.g. Maraviroc), since these
drugs are only active where HIV uses a
specific receptor [66]. Current genotypic
tests that rely on traditional Sanger
sequencing technology are faster and
cheaper than phenotypic tests, but are
also less sensitive where a heterogeneous
(genetically mixed) viral population exists.
But given the ability to sequence every
base position hundreds or even thousands
of times, and thus detect minor variants
within the population, current and future
generations of WGS technologies hold the
potential to match the performance of
phenotypic assays [67–69]. Furthermore,
drug resistance to other anti-retrovirals that
evolves throughout treatment might be
detected earlier by WGS, allowing the
physician to alter the treatment accordingly
[8,70,71]. In fact, this transition is already
underway. Siemens has announced its
intention to make the Trugene HIV-1
Genotyping Assay, which analyses the
protease and reverse transcriptase coding
regions of HIV, compatible with the
Illumina MiSeq [72,73].
Detection and Identification
The potential overall impact on the
diagnostic laboratory is summarised in
Figure 1. As currently configured, it is
unlikely that that WGS will be suitable for
the routine primary detection of a patho-
gen and is unlikely to be applied directly to
a clinical sample, as it would struggle to
detect a pathogen with a low copy number
or that is mixed with the normal micro-
biota [74], without an enrichment step for
pathogen DNA as envisioned by Patho-
genica [75]. Moreover, current detection
tests are generally cheap and fast enough
to satisfy the clinical need. Nevertheless,
metagenomic research is beginning to
suggest possible scenarios in which the
relatively high cost of WGS for detection
may be justified [12,76]. For example, it
has been shown that changes in the
intestinal microbiota precede bloodstream
invasion by vancomycin-resistant Entero-
coccus faecium, and monitoring of at-risk
patients might provide novel opportuni-
ties for treatment intervention [77,78].
Another potential early application of
WGS is the accurate detection of non-
culturable or difficult-to-culture organ-
isms, including fastidious bacteria and
anaerobes [79]. WGS could also be used
in cases where standard diagnostic tests
consistently fail to identify the causative
pathogen, either because it is completely
novel or because it is a variant of a known
pathogen that leads to false negative
results [16,80–82]. In these cases, cheaper
PCR-based tests could then be rapidly de-
veloped and deployed, as occurred during
a recent outbreak of Klebsiella pneumoniae,
with the carbapenemase enzyme OXA-
48, which occurred in the Netherlands
[12,43,81,83].
Lastly, WGS could replace current
PCR-based tests for toxins, as recently
demonstrated for MRSA [23], if the
bacterium in question was already se-
quenced for infection control purposes.
Similarly, it could be used when MALDI-
TOF does not offer the necessary resolu-
tion. Most prominently, MALDI-TOF
cannot distinguish the various serogroups
of Salmonella [21], yet the identification of
enteric fever is crucial for treatment. WGS
for such a narrow purpose alone may not
be cost-effective, but could become a
viable option if the genome data were
also used for epidemiological purposes.
Technical Requirements for
Routine Pathogen WGS
The current generation of sequencers
are designed to sequence human genomes.
For WGS to be cost-effective for much
smaller bacterial genomes, several hun-
dred samples have to be batched, individ-
ually tagged (allowing bioinformatic des-
ignation of sequence back to an individual
isolate), and then pooled at equimolar
amounts. In contrast, clinical practice
demands that the batch sizes are reduced
to a minimum to suit the throughput of a
diagnostic laboratory. To streamline this
process further, sample preparation for
WGS must be simplified, which would
reduce the turnaround time to a few hours
and the need for high-grade technical staff.
In addition, the read-lengths generated
must be sufficiently long to detect linked
resistance mutations [8].
Lastly, WGS must become sensitive
enough to sequence DNA from a single
colony without the need for sub-culturing
or a DNA pre-amplification step, saving a
day of processing time. In this scenario, a
single colony could be picked for pheno-
typic antimicrobial susceptibility testing,
and the remainder used to extract DNA
followed by overnight sequencing. As a
result, both phenotypic susceptibility and
whole-genome epidemiological typing re-
sults could become available in as little as
48 hours from the time of sample arrival.
Existing and near-market platforms such
as 454, Pacific Biosciences, Ion Torrent,
and Illumina MiSeq promise to meet some
of these targets but further evaluation is
needed to assess their utility for routine
clinical practice as opposed to their roles
as tools for research [84]. With regard to
the ease of sample preparation Oxford
Nanopore promises to be very interesting
for pathogen WGS [85].
If the above benchmarks are met, this
will deliver tangible clinical benefits, all
while simplifying the workflows of diag-
nostic laboratories. Given the universality
of pathogen WGS, a wide diagnostic
number of pathogens sequenced is likely to increase over time. Approaches to detection and identification of pathogens and the majority of
susceptibility testing are likely to remain largely unchanged in the near future.
doi:10.1371/journal.ppat.1002824.g001
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repertoire can be offered by a single
machine that will replace multiple different
methodologies, thereby allowing economies
of scale. In this context, it is noteworthy
that WGS analyses a sample in a single
experiment as opposed to requiring multi-
ple subtests. For example, the current HIV
genotyping assay requires seven separate
Sanger sequencing reactions to cover
approximately 1.3 kb of sequence (J. Great-
orex, personal communication). If one of
them fails, the specific reaction might have
to be repeated, thereby complicating the
normal workflows that are key to ensuring
the efficient use of laboratory resources.
WGS would analyse the aforementioned
stretch of the HIV genome in a single step,
removing the potential for this complica-
tion. The same consideration applies to
many of the current typing techniques such
as MIRU-VNTR typing for MTBC (Figure
S1).
An important question is where micro-
bial WGS for diagnostic and public health
purposes will be performed. Regional
sequencing hubs have been developed in
several centres across the United Kingdom
and contain the technical expertise re-
quired for WGS, but alternative models
include centralisation (a specialist refer-
ence laboratory) and decentralisation with
a sequencing platform in most diagnostic
laboratories across the country. This
situation is likely to be fluid and change
as the technology and interpretation tools
develop and mature. Wherever it is
performed, tight quality control of the
entire process will be essential, as others
have discussed in more detail [46,86,87].
Pathogen WGS Data
Interpretation and Use
With commercial companies in strong
competition to develop and market accurate
and affordable sequencing technologies, the
major barrier to their practical implemen-
tation will shift from the issue of hardware to
the software required to analyse the se-
quence data generated [25,52,86,88–92].
Whereas traditional diagnostic tests yield
either binary outputs or at most a handful of
data points, WGS generates huge amounts
of data [3]. Even with current Sanger
sequencing which analyses relatively short
stretches of DNA, human error rather than
sequencing error is often the source of
mistakes in genotyping [86]. Crowd-sourc-
ing (as occurred for E. coli O104:H4
outbreak [43]) to analyse routinely se-
quenced bacteria is not fit for clinical
practice given that the time taken for the
analysis would be significantly longer than
WGS itself, thereby reducing the time
during which clinical interventions to con-
tain outbreaks are possible. Similarly, hav-
ing dedicated bioinformaticians in every
diagnostic laboratory is not realistic. In-
stead, analysis software for WGS is required
to extract clinically relevant information in
a fully automated and reliable fashion
without human intervention (Figure 2) [18].
Ideally, this software should have two key
features. First, it should be platform indepen-
dent, analysing sequence data directly with-
out being tied to proprietary data formats.
This would maintain flexibility and reduce
to a minimum the lag time between the
evaluation of new sequencers and their
clinical use. Second, it should be organism
independent, and be able to perform different
tasks ranging from epidemiological tracking
to susceptibility testing of any organism. In
practice, first-generation interpretation tech-
nology is most likely to be developed for a
small number of key organisms (e.g. HIV,
MRSA, and MTBC) to which other organ-
isms will be added over time.
The utility of interpretation software
will depend on a continuously updated
database that would not only encompass
pathogen genomes to detect transmission
(or lack thereof) but would also contain a
catalogue of point mutations or genes that
account for drug resistance. Samples that
harbour previously unknown mutations in
genes that confer drug resistance or other
clinically relevant bacterial factors could
be flagged for phenotypic follow-up by
reference laboratories. Such information
should be shared internationally [93] (as is
already the case for the breakpoints for
bacterial susceptibility testing [94] or HIV
drug resistance mutations [95]), along with
the routinely collected clinical and epide-
miology data of WGS samples. Potential
obstacles to their release include privacy
concerns [96], questions of authorship
[97], ownership, and intellectual property
[98]. These will need to be tackled to
maximise the possible healthcare benefits
for individual patient care and regional,
national, and international public health,
as well as providing information to the
scientific community to propel the rate of
progress in basic and translational re-
search [43,96,99].
One solution is the creation of an
international, online encyclopaedia divided
into three parts (Figure 2). The first part is a
depository into which accredited diagnostic
laboratories routinely deposit high-quality
WGS data (i.e. draft genomes sequenced to
a certain minimum depth and sequence
quality [100]) from across the world
[49,58,83,87,101], as pioneered by current
MLST websites [102], the NCBI Influenza
Virus Sequence Database [103], and the
UK HIV Drug Resistance Database in
which approximately 90%–95% (.51,000
tests) of all HIV genotypic drug resistance
test data in the United Kingdom are
represented [104]. This would include an
open access user-friendly interface to re-
construct phylogenetic trees of whole
genomes or single genes of interest. This
could be coupled with a layered approach
in which specific users have access to
additional information. For example, na-
tional public health organisations could link
clinical and genomic data for patient
groups to provide the opportunity for more
detailed analyses, while international orga-
nisations such as the European Centre for
Disease Control or the WHO could have
access to genomic information and limited
anonymised clinical data from multiple
countries to monitor cross-border spread
of microbial pathogens and coordinate
international interventions as appropriate
[87,101]. Online storage of only anon-
ymised data would protect patient confi-
dentiality. Nevertheless, making such infor-
mation publicly available in a routine
fashion is controversial, particularly since
this might deter patients from seeking
testing for some diseases. Given the immi-
nent transition of WGS into the clinic we
would encourage a timely debate of this
issue by patients and their advocates,
scientists, clinicians, ethicists, and policy
makers [105].
The second part of the encyclopaedia
could provide a forum to discuss new
hypotheses (as piloted by PLoS Currents:
Influenza) and, ultimately, to propose new
markers for in vitro drug resistance, to link
the genotype directly to disease outcome,
or to identify novel pathogens [106,107].
When warranted, new markers could be
reviewed by an expert panel and added to
the third part of the encyclopaedia, a read-
only diagnostic database that contains a
catalogue of all of the known mutations or
genes of clinical importance. This process
could be modelled after the European
Committee on Antimicrobial Susceptibili-
ty Testing (EUCAST), which has used
standardised methodologies to successfully
harmonise and regularly review break-
points for phenotypic susceptibility testing
across Europe [94], and the Stanford HIV
Drug Resistance Database [95]. The
proposed encyclopaedia represents an
infrastructure project that would require
sustained funding [87,91,108].
Implications for Reference
Laboratories
The implementation of WGS as a
routine clinical tool as well as the collation
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Figure 2. Overview of pathogen WGS data interpretation and use. After an enrichment step for pathogen DNA via culture or direct
molecular enrichment/amplification (e.g. by RT-PCR for HIV) from the clinical sample, WGS could be performed in regional sequencing hubs. Fully
automated analysis software would extract information of immediate clinical importance (i.e. an epidemiological analysis, susceptibility testing, and/
or the precise identity of the pathogen). The results would be presented such that no knowledge of genomics would be required. Only in cases of
new and emerging types of concern, where the genotype-phenotype relationship was unclear, or for quality control (QC) purposes would samples be
sent for analysis by reference laboratories. Reference laboratories could routinely make anonymised sequence data available in the first part of an
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and expert oversight of these data by a
public health organisation would represent
a very powerful sentinel surveillance
system. In theory, this could be funded
by resources released by a reduced need
for the phenotypic and genotypic tests
currently performed by reference labora-
tories, although such a transition would be
complex. Future central activities could
include monitoring of the emergence,
mechanisms, and global transmission of
antimicrobial resistance, and the relation-
ship between microbial genetic markers
and patient outcome. Access to multiple
genome sequences would also provide the
opportunity to assess the conservation of
potential targets for drugs or vaccines
[14,35,109–111].
The following example gives a clear
demonstration of the potential of this new
paradigm: a recent study has found that
strains of MRSA that cannot be detected
by the current PCR assay targeting mecA
have been circulating at a low frequency in
the United Kingdom and Denmark for at
least 36 years [81]. In a scenario where
WGS was in widespread use, the genome
sequence data together with periodic
comparisons of genotype with phenotype
would have identified such isolates. This
could have triggered a national preva-
lence survey, experimental characterisa-
tion, and timely improvements in assays
to close the gap in detection capability.
Reference laboratories could call upon
the isolating laboratories to supply sam-
ples of interest to perform targeted
research to gain vital insights into new
and emerging pathogens before they
cause major outbreaks rather than merely
reacting to these events. To enable this
process, it will be necessary for diagnostic
laboratories to store their bacterial iso-
lates, at least temporarily, which is not
always routine at present.
Conclusion
WGS represents the opportunity for a
step-change in diagnostic microbiological
practice that in the long term could be
associated with little or no increase in
overall cost. Although the sequencing
technologies will change over time, whole
genome microbial epidemiology repre-
sents the ultimate source of information
and will not be superseded. However,
WGS will only replace some of the current
diagnostic tests and will initially be target-
ed to specific samples or pathogens based
on provision of comparable information to
that currently obtainable but with a
reduced turnaround time and/or cost, or
the generation of information that is not
currently available. This will require the
development of fully automated sequence
interpretation software, the provision of
clinically relevant information in a format
that can be understood and acted upon by
healthcare workers with no specialist
knowledge of genome sequencing, and
the creation of systems for gathering and
interpreting genome data at a population
and public health level. In an age in which
the further spread of drug resistance and
the emergence of new pathogens are
predicted [112], we can equip ourselves
with the tools to detect, monitor, and
control these threats to human health in
real time.
Supporting Information
Figure S1 Current diagnostic paradigm
for MTBC compared with the use of
WGS. According to the current diagnostic
paradigm for Mycobacterium tuberculosis com-
plex (MTBC), clinical samples (usually
sputum) are first analysed using smear
microscopy to detect high numbers of
acid-fast bacilli. In parallel, cultures are
inoculated (usually in liquid MGIT cul-
tures), which yield positive results within 1
to 6 weeks. Positive cultures are then re-
examined using smear microscopy to rule
out contaminants or false-positive results
and sent to a reference laboratory for
speciation using molecular techniques
such as DNA-hybridisation. These assays
can also be used to detect drug resistance
but have only been able to partly replace
phenotypic tests because they target a
limited number of resistance loci [60].
Similarly, the small number of DNA
probes in commercial assays used to
identify the precise member of MTBC
results in the misclassification of some
species or sub-species. Most prominently,
only some but not all strains of M. canettii,
which are intrinsically resistant against
pyrazinamide, and potentially the novel
agent PA-824 can be identified [113–115].
Therefore, phenotypic testing is still re-
quired. Some epidemiological typing tech-
niques can be performed directly from the
clinical sample, but in practice, they are
generally performed at reference labora-
tories (figure adapted from Future Micro-
biology 2008; 3: 405–13 [60] based on
[116,117] with permission of the authors
and Future Medicine Ltd.). In a future
WGS paradigm, all functions could be
performed in regional laboratories. First,
the Cepheid Xpert TB/RIF test in
combination with smear microscopy could
be used to rapidly distinguish MTBC from
other acid-fast bacteria and to detect
rifampicin resistance. Provided that the
resistance mechanisms for the various anti-
tubercular drugs are elucidated more fully
than is currently the case [118], WGS
directly from the initial MGIT liquid
culture could not only identify the precise
sub-species but also detect resistance to all
remaining drugs, and allow for epidemio-
logical studies at the ultimate resolution
[28,37,63].
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